Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Subscribe To Our Newsletter & Stay Updated